✨ Free AI Report
Instil Bio, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Instil Bio, Inc.
Company Research

Instil Bio, Inc.: Business Overview, Financials & Competitive Analysis

Instil Bio is a clinical-stage biopharmaceutical company developing a pipeline of cell therapies, specifically autologous tumor infiltrating lymphocyte (TIL) therapies for cancer treatment. The company was incorporate...

Analyst-debate audio for Instil Bio, Inc.

AskCyborg analysts argue the bull and bear cases for Instil Bio, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Weak

Cyborg Score thesis

Early-stage TIL cell therapy company with promising platform but severe near-term cash burn risk and market execution...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Immunotherapy/Cell Therapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Instil Bio, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Instil Bio, Inc. Overview

Pro stress-test →

Instil Bio is a clinical-stage biopharmaceutical company developing a pipeline of cell therapies, specifically autologous tumor infiltrating lymphocyte (TIL) therapies for cancer treatment. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Strategic Profile

Pro stress-test →

The company focuses on engineered tumor infiltrating lymphocyte (TIL) cell therapies using its proprietary Co-Stimulatory Antigen Receptor (CoStAR) platform. Its lead candidate AXN-2510/IMM2510 is in Phase 1b/2 trials for advanced/metastatic non-small cell lung cancer, with additional Phase 1 studies in China exploring multiple solid tumor types.

Competitive Landscape

Pro stress-test →

Instil Bio competes in the CAR-T/TIL cell therapy space dominated by larger players like Novartis (Kymriah), Gilead (Yescarta), and emerging competitors like Iovance Biotherapeutics and Legend Biotech. TIL therapies represent a growing but smaller segment compared to CAR-T. Competitive advantages lie in CoStAR platform differentiation and FRA-targeting focus, though limited resources constrain development speed versus well-funded competitors.

Industry Context

Instil Bio, Inc. operates in Biopharmaceutical - Immunotherapy/Cell Therapy.

Key facts

Founded: 2018 · Headquarters: Dallas, United States · Employees: 14 · Market cap: $44.8M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Instil Bio, Inc..

  • Proprietary CoStAR platform targeting folate receptor alpha for multiple solid tumors including ovarian, uterine, and lung cancers
  • Market cap severely compressed to $44.8M, indicating significant market skepticism
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Jan 2026Stock trading significantly below 52-week highs amid clinical trial execution concerns
  • RecentPhase 1b/2 continuation for AXN-2510 in lung cancer with parallel China trials
  • +1 moreTrack every material event for Instil Bio, Inc. as it happens. Explore monitoring →
Get alerted when Instil Bio, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

KymriahCAR-T cell therapy for hematologic malignancies→YescartaCAR-T cell therapy for lymphomas→Afamitresgene AutoleucelTIL cell therapy for melanoma→

Compare Instil Bio, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Instil Bio, Inc. operates in Biopharmaceutical - Immunotherapy/Cell Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Immunotherapy/Cell Therapy research →
NEW · MCP server

Ask your AI assistant about Instil Bio, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Instil Bio, Inc. and its top competitor on Cyborg Score”
“What did Instil Bio, Inc. do this quarter?”
“Is Instil Bio, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Instil Bio, Inc. do?+
Instil Bio is a clinical-stage biopharmaceutical company developing a pipeline of cell therapies, specifically autologous tumor infiltrating lymphocyte (TIL) therapies for cancer treatment. The company was incorporate...
What is Instil Bio, Inc.'s Cyborg Score?+
Instil Bio, Inc. has a Cyborg Score of 3/10 (Weak). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Instil Bio, Inc.'s main competitors?+
Named competitors include Kymriah, Yescarta, Afamitresgene Autoleucel. The full competitive landscape is in the AskCyborg report.
How can I get the full Instil Bio, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Instil Bio, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Instil Bio, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Immunotherapy research

Companies in the same sector and named competitors, ranked by Cyborg Score.

5XBiotech Inc.